litlas
ログインアカウント作成

Vera Hirsh

1989–2023 年に発表

58
論文数
30,098
被引用数
49
h 指数
58
i10 指数

被引用数

Vera Hirsh の年別被引用数1989 年: 被引用 1 件1990 年: 被引用 2 件1992 年: 被引用 2 件1993 年: 被引用 2 件1994 年: 被引用 1 件1997 年: 被引用 2 件1999 年: 被引用 2 件2000 年: 被引用 4 件2001 年: 被引用 7 件2002 年: 被引用 15 件2003 年: 被引用 15 件2004 年: 被引用 36 件2005 年: 被引用 51 件2006 年: 被引用 124 件2007 年: 被引用 142 件2008 年: 被引用 138 件2009 年: 被引用 176 件2010 年: 被引用 217 件2011 年: 被引用 235 件2012 年: 被引用 230 件2013 年: 被引用 341 件2014 年: 被引用 368 件2015 年: 被引用 466 件2016 年: 被引用 364 件2017 年: 被引用 357 件2018 年: 被引用 341 件2019 年: 被引用 1,036 件2020 年: 被引用 857 件2021 年: 被引用 764 件2022 年: 被引用 475 件2023 年: 被引用 310 件2024 年: 被引用 411 件2025 年: 被引用 177 件2026 年: 被引用 5 件1991 年は被引用が無いため表示していません1995〜1996 年は被引用が無いため表示していません1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,337 件、この内訳の 24.3%中国: 引用元論文 1,119 件、この内訳の 11.6%日本: 引用元論文 560 件、この内訳の 5.8%イタリア: 引用元論文 553 件、この内訳の 5.8%イギリス: 引用元論文 474 件、この内訳の 4.9%ドイツ: 引用元論文 413 件、この内訳の 4.3%フランス: 引用元論文 389 件、この内訳の 4%カナダ: 引用元論文 366 件、この内訳の 3.8%スペイン: 引用元論文 333 件、この内訳の 3.5%韓国: 引用元論文 310 件、この内訳の 3.2%スイス: 引用元論文 244 件、この内訳の 2.5%オランダ: 引用元論文 244 件、この内訳の 2.5%
0%24.3%その他 23.8%

機関

分野

  • Medicine78.7%
  • Biochemistry, Genetics and Molecular Biology14.2%
  • Immunology and Microbiology2.2%
  • Chemistry1%
  • Materials Science0.8%
  • Mathematics0.6%
  • その他2.5%

トピック

  • Lung Cancer Treatments and Mutations19%
  • Lung Cancer Research Studies8.1%
  • Lung Cancer Diagnosis and Treatment6.1%
  • Cancer Immunotherapy and Biomarkers4%
  • Cancer Genomics and Diagnostics3.9%
  • Colorectal Cancer Treatments and Studies3.4%
  • その他55.5%

共著者

全論文

検索で開く
  1. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

    著者: Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, С. В. Орлов, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler - Journal of Clinical Oncology 2013 被引用: 3,198

  2. Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

    著者: Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne - New England Journal of Medicine 2013 被引用: 3,406

  3. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

    著者: Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne, Li Zhang, Michael Boyer, Tony Mok, Vera Hirsh, James Chih‐Hsin Yang, Ki Hyeong Lee, Shun Lü, Yuankai Shi, Sang-We Kim, Janessa Laskin, Dong‐Wan Kim, Catherine Dubos Arvis, Karl Kölbeck, Scott A. Laurie, Chun-Ming Tsai, Mehdi Shahidi, Miyoung Kim, Dan Massey, Victoria Zazulina, Luis Paz‐Ares - The Lancet Oncology 2016 被引用: 1,175

  4. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

    著者: James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, Martin Sebastian, Sanjay Popat, Nobuyuki Yamamoto, Caicun Zhou, Cheng-Ping Hu, Kenneth J. O’Byrne, Jifeng Feng, Shun Lü, Yunchao Huang, Sarayut Lucien Geater, Kye Young Lee, Chun-Ming Tsai, В. А. Горбунова, Vera Hirsh, Jaafar Bennouna, С. В. Орлов, Tony Mok, Michael Boyer, Wu‐Chou Su, Ki Hyeong Lee, Terufumi Kato, Dan Massey, Mehdi Shahidi, Victoria Zazulina, Lecia V. Sequist - The Lancet Oncology 2015 被引用: 1,580

  5. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

    著者: Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel de Castro, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano Van Kooten, Mircea Dediu, B. Findlay, Dongsheng Tu, D. Johnston, Andrea Bezjak, Gary M. Clark, P. Santabárbara, Lesley Seymour - New England Journal of Medicine 2005 被引用: 5,451

  6. Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

    著者: Mark A. Socinski, Igor Bondarenko, Nina Karaseva, Anatoly Makhson, Igor Vynnychenko, Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Paul Bhar, Hui Zhang, J. L. Mesías Iglesias, Markus F. Renschler - Journal of Clinical Oncology 2012 被引用: 754

  7. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

    著者: Luis Paz‐Ares, E.H. Tan, Kenneth J. O’Byrne, L. Zhang, Vera Hirsh, Michael Boyer, James Chih‐Hsin Yang, Tony Mok, K.H. Lee, Shun Lü, Yajun Shi, D. H. Lee, Janessa Laskin, D.-W. Kim, Scott A. Laurie, Karl Kölbeck, Jean Fan, Nigel Dodd, Angela Märten, K. Park - Annals of Oncology 2017 被引用: 522

  8. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

    著者: Vincent A. Miller, Vera Hirsh, Jacques Cadranel, Yuh-Min Chen, Keunchil Park, Sang-We Kim, Caicun Zhou, Wu‐Chou Su, Mengzhao Wang, Yan Sun, Dae Seog Heo, Lucio Crinò, Eng-Huat Tan, Tsu-Yi Chao, Mehdi Shahidi, Xiuyu Julie Cong, Robert M. Lorence, James Chih‐Hsin Yang - The Lancet Oncology 2012 被引用: 953

  9. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

    著者: David H. Henry, Luís Costa, François Goldwasser, Vera Hirsh, Vânia Hungria, Jana Prausová, Giorgio V. Scagliotti, H.P. Sleeboom, Andrew Spencer, Saroj Vadhan‐Raj, Roger von Moos, Wolfgang Willenbacher, Penella J. Woll, Jianming Wang, Qi Jiang, Susie Jun, Roger Dansey, Howard Yeh - Journal of Clinical Oncology 2011 被引用: 1,262

  10. Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer

    著者: Jay Kumar Raghavan Nair, Umar Saeed, Connor C. McDougall, Ali Sabri, Bojan Kovacina, B. V. S. Raidu, Riaz Ahmed Khokhar, Stephan Probst, Vera Hirsh, Jeffrey Chankowsky, Léon C.L.T. van Kempen, Jana Taylor - Canadian Association of Radiologists Journal 2020 被引用: 89

  11. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

    著者: Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Victoria Zazulina, Mehdi Shahidi, Martin Schüler - Journal of Clinical Oncology 2023 被引用: 48

  12. Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

    著者: Martin Reck, Joachim von Pawel, Petr Zatloukal, Rodryg Ramlau, Vera Gorbounova, Vera Hirsh, Natasha B. Leighl, J. Mezger, Venice Archer, N. Moore, Christian Manegold - Journal of Clinical Oncology 2009 被引用: 1,511

  13. Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer

    著者: U. Gatzemeier, G. Groth, Charles Butts, Nico van Zandwijk, Frances A. Shepherd, Andrea Ardizzoni, Claire Barton, Parviz Ghahramani, Vera Hirsh - Annals of Oncology 2003 被引用: 384

  14. First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

    著者: Martin Schüler, Yi‐Long Wu, Vera Hirsh, Kenneth J. O’Byrne, Nobuyuki Yamamoto, Tony Mok, Sanjay Popat, Lecia V. Sequist, Dan Massey, Victoria Zazulina, James Chih‐Hsin Yang - Journal of Thoracic Oncology 2016 被引用: 356

  15. Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer

    著者: Giorgio V. Scagliotti, Joachim von Pawel, Silvia Novello, Rodryg Ramlau, Adolfo Favaretto, Fabrice Barlési, Wallace Akerley, С. В. Орлов, Armando Santoro, David R. Spigel, Vera Hirsh, Frances A. Shepherd, Lecia V. Sequist, Alan N. Sandler, Jeffrey S. Ross, Qiang Wang, Reinhard von Roemeling, Dale E. Shuster, Brian Schwartz - Journal of Clinical Oncology 2015 被引用: 260

  16. Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

    著者: Giorgio V. Scagliotti, Vera Hirsh, Salvatore Siena, David H. Henry, Penella J. Woll, Christian Manegold, Philippe Solal‐Céligny, Gladys Rodriguez, Maciej Krzakowski, Nilesh Mehta, Lara Lipton, José Á. García-Sáenz, José Rodrigues Pereira, Kumar Prabhash, Tudor–Eliade Ciuleanu, Vladimir Kanarev, Huei Wang, Arun Balakumaran, Ira Jacobs - Journal of Thoracic Oncology 2012 被引用: 340

  17. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

    著者: Martin Reck, Joachim von Pawel, Petr Zatloukal, Rodryg Ramlau, V. Gorbounova, Vera Hirsh, N. B. Leighl, J. Mezger, Venice Archer, Norman C. Moore, C. Manegold - Annals of Oncology 2010 被引用: 644

  18. Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

    著者: James Chih‐Hsin Yang, Vera Hirsh, Martin Schüler, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Tony Mok, Victoria Zazulina, Mehdi Shahidi, Juliane Lungershausen, Dan Massey, Michael Palmer, Lecia V. Sequist - Journal of Clinical Oncology 2013 被引用: 321

  19. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

    著者: James Chih‐Hsin Yang, Lecia V. Sequist, Caicun Zhou, Martin Schüler, Sarayut Lucien Geater, Tony Mok, Chengping Hu, Nobuyuki Yamamoto, J. Feng, Kenneth J. O’Byrne, Shun Lü, Vera Hirsh, Yunchao Huang, Martin Sebastian, I. Okamoto, Nicolas Dickgreber, Riyaz Shah, Angela Märten, Dan Massey, Sven Wind, Yi‐Long Wu - Annals of Oncology 2016 被引用: 188

  20. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

    著者: David H. Henry, Saroj Vadhan‐Raj, Vera Hirsh, Roger von Moos, Vânia Hungria, Luís Costa, Penella J. Woll, Giorgio V. Scagliotti, Geoffrey Smith, Amy Feng, Susie Jun, Roger Dansey, Howard Yeh - Supportive Care in Cancer 2013 被引用: 182

  21. Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

    著者: Vera Hirsh, Luis Paz‐Ares, Michael Boyer, Rafael Rosell, Gary Middleton, Wilfried Eberhardt, Aleksandra Szczęsna, Pavel Reiterer, Mansoor N. Saleh, Óscar Arrieta, Emilio Bajetta, R. Timothy Webb, Johannes Isaac Raats, Rebecca Benner, Camilla Fowst, Sandra J. Meech, David Readett, Joan H. Schiller - Journal of Clinical Oncology 2011 被引用: 139

  22. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

    著者: Edward S. Kim, Vera Hirsh, Tony Mok, Mark A. Socinski, Radj Gervais, Yi‐Long Wu, Long-Yun Li, Claire Watkins, Mark V. Sellers, Elizabeth Lowe, Yan Sun, Mei‐Lin Liao, Kell Østerlind, Martin Reck, Alison Armour, Frances A. Shepherd, Scott M. Lippman, Jean‐Yves Douillard - The Lancet 2008 被引用: 1,243

  23. Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors

    著者: Lee S. Rosen, David Gordon, N. Simon Tchekmedyian, Ronald Yanagihara, Vera Hirsh, Maciej Krzakowski, Marek Pawlicki, Paul de Souza, Ming Zheng, Gladys Urbanowitz, Dirk J. Reitsma, John J. Seaman, On behalf of the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group - Cancer 2004 被引用: 716

  24. Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

    著者: Christian Manegold, Donald Gravenor, Donald Woytowitz, J. Mezger, Vera Hirsh, Gary Albert, Mohammed Al-Adhami, David Readett, Arthur Μ. Krieg, Cynthia G. Leichman - Journal of Clinical Oncology 2008 被引用: 169